DSGN

Rating neutralAI MemoPost-earnings T+3

Design Therapeutics

As of 2026-08-13/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 operating update and RESTORE-FA redesign • 2026-08-03

Base target: $14 / p=45% prob

Biggest risk

The thesis remains dependent on small clinical cohorts and future biomarker-to-clinical validation. RESTORE-FA endpoint and cohort modifications, delayed FECD data, and sparse independent coverage leave meaningful execution and disappointment risk.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Positive four-week RESTORE-FA data showed dose-dependent increases in endogenous frataxin mRNA and protein alongside improvements across multiple clinical measures, while the company maintains substantial cash resources and advances DT-818 [#SEC-8K-2026-08-03].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-13

Base target

$14

p=45%

Bull target

$25

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

RESTORE-FA 12-week data
DT-818 DM1 Phase 1 data
Positive four-week RESTORE-FA data showed dose-dependent increases in endogenous frataxin mRNA and protein alongside improvements across multiple clinical measures, while the company maintains substantial cash resources and advances DT-818 [#SEC-8K-2026-08-03].

BearKey bullets

Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
FECD Phase 2 biomarker data moved to 2027 because of delayed DT-168 eye-dropper supply [#SEC-8K-2026-08-03].
RESTORE-FA remains a binary clinical development program, and four-week biomarker or exploratory clinical improvements may not translate into durable 12-week or registrational evidence [#SEC-8K-2026-08-03].

WatchKey bullets

Q2 2026 operating update and RESTORE-FA redesign

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $14 (p=45%)

Target spread vs base: +79% / -50%

Scenario probabilities

Bull Target: $25 (p=20%)Base Target: $14 (p=45%)Bear Target: $7 (p=35%)

Commentary

The primary Q2 release is constructive on program progress and cash runway, but forward visibility is concentrated in Q4 2026 registrational planning and Q1 2027 RESTORE-FA data. The earnings queue labels August 10, while the available company release and SEC exhibit are dated August 3; the primary filing date is used here. No reliable post-print analyst revision or target-change set was available, so the view remains monitoring-oriented despite the reported $21 median target.

As of 2026-08-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

RESTORE-FA 12-week data
DT-818 DM1 Phase 1 data

Scenarios

Bull Target (Scenario probability)

$25 / p=20% prob

Base Target (Scenario probability)

$14 / p=45% prob

Bear Target (Scenario probability)

$7 / p=35% prob

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-03
Q2 2026 operating update and RESTORE-FA redesign
The company reported $207.4 million of cash and securities, initiated DT-818 dosing in DM1, and modified RESTORE-FA around a planned 1 mpk dose, a 12-week cohort, and an FXN protein endpoint [#SEC-8K-2026-08-03].
Prob 85.00% • Move 8.00% • Priced-in 75.00%
EVENT2026-11-11
RESTORE-FA registrational-plan update
Management expects to provide an update on registrational plans for DT-216P2 in the fourth quarter of 2026 [#SEC-8K-2026-08-03].
Prob 70.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

RESTORE-FA 12-week data
2027-08-13
Data from the 12-week treatment cohort is expected in the first quarter of 2027. Positive biomarker and clinical findings could materially de-risk DT-216P2, but the outcome remains binary [#SEC-8K-2026-08-03].
Prob 55% • Move 35% • Priced-in 30%
DT-818 DM1 Phase 1 data
2027-08-13
Patient dosing has begun in the Phase 1 multiple-ascending-dose trial of DT-818, with data anticipated in 2027 [#SEC-8K-2026-08-03].
Prob 45% • Move 20% • Priced-in 15%

Risks

Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
FECD Phase 2 biomarker data moved to 2027 because of delayed DT-168 eye-dropper supply [#SEC-8K-2026-08-03].
RESTORE-FA remains a binary clinical development program, and four-week biomarker or exploratory clinical improvements may not translate into durable 12-week or registrational evidence [#SEC-8K-2026-08-03].
The company changed the ongoing RESTORE-FA cohorts and primary efficacy endpoint, increasing execution and interpretability risk [#SEC-8K-2026-08-03].
The company reported a $20.2 million second-quarter net loss and $16.4 million of R&D expense; the reported cash runway is strong but remains exposed to pipeline spending and future financing needs [#PR-EARNINGS-2026-08-03].

Peers

Symbol	Summary
ABUS	Loose same-sector small-cap biopharma comparator; useful mainly for development-stage and financing-risk context, not a direct indication peer.
KURA	Loose same-sector small-cap oncology comparator; relevant for clinical-stage volatility but not directly comparable to DSGN's rare-disease GeneTAC programs.
OLMA	Similar-market-cap biotech screening comparator; limited operating comparability and should not drive valuation conclusions.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-13

Loading AI feed…

Symbol

Summary

ABUS

Loose same-sector small-cap biopharma comparator; useful mainly for development-stage and financing-risk context, not a direct indication peer.

KURA

Loose same-sector small-cap oncology comparator; relevant for clinical-stage volatility but not directly comparable to DSGN's rare-disease GeneTAC programs.

OLMA

Similar-market-cap biotech screening comparator; limited operating comparability and should not drive valuation conclusions.